Humán interferon-α orális szilárd gyógyszerformába történo feldolgozása

Translated title of the contribution: Formulation of an oral solid dosage form containing human interferon-α

Kristó Katalin, Bajdik János, A. Márki, I. Erös, G. Falkay, K. Pintye-Hódi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The main objective of this study was to process the human á-interferon for the solid dosage form. The first step was the preparation of the intermediate product for the tablet making. Fluid bed apparatus with top spray method was applied for the layering of powdered cellulose with human α-interferon solutions. The intermediate product was compressed into tablet and an enteric solvent coating of the tablets was made in a fluid bed apparatus with Wurster method. The physical parameters were detected. These fitted the Ph. Eur. and the mechanical properties of the tablets were appropriate for coating in fluid bed apparatus. The tablets agree with the requirements of Ph. Eur. and the active agent was not dissolved in gastric juice. An animal test was also performed. The human α-interferon in the blood of the animals was detected with ELISA method. The human α-interferon specific kit was used. The active ingredient dissolved from the tablets was absorbed from the ileum. The solid dosage form containing human α-interferon was prepared; this can make oral application of human α-interferon possible.

Original languageHungarian
Pages (from-to)31-35
Number of pages5
JournalActa Pharmaceutica Hungarica
Volume78
Issue number1
Publication statusPublished - 2008

Fingerprint

Dosage Forms
Interferons
Tablets
Gastric Juice
Ileum
Cellulose
Enzyme-Linked Immunosorbent Assay

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Humán interferon-α orális szilárd gyógyszerformába történo feldolgozása. / Katalin, Kristó; János, Bajdik; Márki, A.; Erös, I.; Falkay, G.; Pintye-Hódi, K.

In: Acta Pharmaceutica Hungarica, Vol. 78, No. 1, 2008, p. 31-35.

Research output: Contribution to journalArticle

@article{3aecc3cfa63e4c98b5a016e4b2a653fb,
title = "Hum{\'a}n interferon-α or{\'a}lis szil{\'a}rd gy{\'o}gyszerform{\'a}ba t{\"o}rt{\'e}no feldolgoz{\'a}sa",
abstract = "The main objective of this study was to process the human {\'a}-interferon for the solid dosage form. The first step was the preparation of the intermediate product for the tablet making. Fluid bed apparatus with top spray method was applied for the layering of powdered cellulose with human α-interferon solutions. The intermediate product was compressed into tablet and an enteric solvent coating of the tablets was made in a fluid bed apparatus with Wurster method. The physical parameters were detected. These fitted the Ph. Eur. and the mechanical properties of the tablets were appropriate for coating in fluid bed apparatus. The tablets agree with the requirements of Ph. Eur. and the active agent was not dissolved in gastric juice. An animal test was also performed. The human α-interferon in the blood of the animals was detected with ELISA method. The human α-interferon specific kit was used. The active ingredient dissolved from the tablets was absorbed from the ileum. The solid dosage form containing human α-interferon was prepared; this can make oral application of human α-interferon possible.",
author = "Krist{\'o} Katalin and Bajdik J{\'a}nos and A. M{\'a}rki and I. Er{\"o}s and G. Falkay and K. Pintye-H{\'o}di",
year = "2008",
language = "Hungarian",
volume = "78",
pages = "31--35",
journal = "Acta Pharmaceutica Hungarica",
issn = "0001-6659",
publisher = "Magyar Gyogyszereszeti Tarsasag",
number = "1",

}

TY - JOUR

T1 - Humán interferon-α orális szilárd gyógyszerformába történo feldolgozása

AU - Katalin, Kristó

AU - János, Bajdik

AU - Márki, A.

AU - Erös, I.

AU - Falkay, G.

AU - Pintye-Hódi, K.

PY - 2008

Y1 - 2008

N2 - The main objective of this study was to process the human á-interferon for the solid dosage form. The first step was the preparation of the intermediate product for the tablet making. Fluid bed apparatus with top spray method was applied for the layering of powdered cellulose with human α-interferon solutions. The intermediate product was compressed into tablet and an enteric solvent coating of the tablets was made in a fluid bed apparatus with Wurster method. The physical parameters were detected. These fitted the Ph. Eur. and the mechanical properties of the tablets were appropriate for coating in fluid bed apparatus. The tablets agree with the requirements of Ph. Eur. and the active agent was not dissolved in gastric juice. An animal test was also performed. The human α-interferon in the blood of the animals was detected with ELISA method. The human α-interferon specific kit was used. The active ingredient dissolved from the tablets was absorbed from the ileum. The solid dosage form containing human α-interferon was prepared; this can make oral application of human α-interferon possible.

AB - The main objective of this study was to process the human á-interferon for the solid dosage form. The first step was the preparation of the intermediate product for the tablet making. Fluid bed apparatus with top spray method was applied for the layering of powdered cellulose with human α-interferon solutions. The intermediate product was compressed into tablet and an enteric solvent coating of the tablets was made in a fluid bed apparatus with Wurster method. The physical parameters were detected. These fitted the Ph. Eur. and the mechanical properties of the tablets were appropriate for coating in fluid bed apparatus. The tablets agree with the requirements of Ph. Eur. and the active agent was not dissolved in gastric juice. An animal test was also performed. The human α-interferon in the blood of the animals was detected with ELISA method. The human α-interferon specific kit was used. The active ingredient dissolved from the tablets was absorbed from the ileum. The solid dosage form containing human α-interferon was prepared; this can make oral application of human α-interferon possible.

UR - http://www.scopus.com/inward/record.url?scp=41749119638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41749119638&partnerID=8YFLogxK

M3 - Article

C2 - 18476366

AN - SCOPUS:41749119638

VL - 78

SP - 31

EP - 35

JO - Acta Pharmaceutica Hungarica

JF - Acta Pharmaceutica Hungarica

SN - 0001-6659

IS - 1

ER -